Russia's Plot to Kill a German Defense CEO
Armin Papperger, the chief executive officer of Rheinmetall AG, Germany's largest defense company, became a Russian target following the full-scale invasion of Ukraine as Rheinmetall provided Ukraine with armored vehicles, military trucks, and ammunition. Stephanie Baker has the details in today's 'Big Take' on Bloomberg Television. (Source: Bloomberg)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Cboe Global Markets Reports Trading Volume for July 2025
CHICAGO, Aug. 5, 2025 /PRNewswire/ -- Cboe Global Markets, Inc. (Cboe: CBOE), the world's leading derivatives and securities exchange network, today reported July monthly trading volume statistics across its global business lines. The data sheet "Cboe Global Markets Monthly Volume & RPC/Net Revenue Capture Report" contains an overview of certain July trading statistics and market share by business segment, volume in select index products, and RPC/net capture, which is reported on a one-month lag, across business lines. Average Daily Trading Volume (ADV) by Month Year-To-Date Jul 2025 Jul 2024 % Chg Jun 2025 % Chg Jul 2025 Jul 2024 % Chg Multiply-listed options (contracts, k) 12,215 11,145 9.6 % 11,836 3.2 % 12,886 10,642 21.1 % Index options (contracts, k) 4,469 4,140 8.0 % 4,639 -3.7 % 4,688 4,065 15.3 % Futures (contracts, k)1 178 267 -33.3 % 185 -3.8 % 226 242 -6.3 % U.S. Equities - On-Exchange (matched shares, mn) 1,790 1,280 39.9 % 1,780 0.6 % 1,785 1,404 27.2 % U.S. Equities - Off-Exchange (matched shares, mn) 141 76 84.8 % 123 14.4 % 113 78 45.2 % Canadian Equities (matched shares, k) 150,096 122,608 22.4 % 146,058 2.8 % 154,298 144,633 6.7 % European Equities (€, mn) 12,490 9,229 35.3 % 11,811 5.7 % 13,560 9,665 40.3 % Cboe Clear Europe Cleared Trades (k) 122,973 105,831 16.2 % 110,623 11.2 % 935,981 699,176 33.9 % Cboe Clear Europe Net Settlements (k) 1,236 1,022 20.9 % 1,090 13.4 % 7,726 6,311 22.4 % Australian Equities (AUD, mn) 870 771 12.8 % 951 -8.5 % 884 764 15.7 % Global FX ($, mn) 48,514 45,586 6.4 % 51,222 -5.3 % 53,135 46,340 14.7 % 1 In the second quarter of 2025, Digital futures products were transitioned to Cboe Futures Exchange. Futures metrics prior to the second quarter of 2025 exclude Digital futures products. July 2025 Trading Volume Highlights U.S. Options Cboe's S&P 500 Index (SPX) and Mini-SPX Index (XSP) options set monthly volume records in zero-days-to-expiry (0DTE) trading, with 0DTE ADVs of 2.2 million and 60 thousand contracts, respectively. SPX options recorded its third most active trading day of all time on July 31 with 4.8 million contracts traded. European Equities Cboe Europe Equities hit record market shares in July for both overall trading (26.6%) and continuous trading (34.7%). About Cboe Global MarketsCboe Global Markets (Cboe: CBOE), the world's leading derivatives and securities exchange network, delivers cutting-edge trading, clearing and investment solutions to people around the world. Cboe provides trading solutions and products in multiple asset classes, including equities, derivatives and FX across North America, Europe and Asia Pacific. Above all, we are committed to building a trusted, inclusive global marketplace that enables people to pursue a sustainable financial future. To learn more about the Exchange for the World Stage, visit Cboe Media ContactsCboe Analyst Contact Angela Tu Tim CaveKenneth Hill, CFA +1-917-985-1496 +44 (0) 7593-506-719+1-312-786-7559 atu@ tcave@ CBOE-V Cboe®, Cboe Global Markets®, Cboe Volatility Index®, and VIX® are registered trademarks of Cboe Exchange, Inc. or its affiliates. Standard & Poor's®, S&P®, SPX®, and S&P 500® are registered trademarks of Standard & Poor's Financial Services, LLC, and have been licensed for use by Cboe Exchange, Inc. All other trademarks and service marks are the property of their respective owners. Any products that have the S&P Index or Indexes as their underlying interest are not sponsored, endorsed, sold or promoted by Standard & Poor's or Cboe and neither Standard & Poor's nor Cboe make any representations or recommendations concerning the advisability of investing in products that have S&P indexes as their underlying interests. All other trademarks and service marks are the property of their respective owners. Cboe Global Markets, Inc. and its affiliates do not recommend or make any representation as to possible benefits from any securities, futures or investments, or third-party products or services. Cboe Global Markets, Inc. is not affiliated with S&P. Investors should undertake their own due diligence regarding their securities, futures, and investment practices. This press release speaks only as of this date. Cboe Global Markets, Inc. disclaims any duty to update the information herein. Nothing in this announcement should be considered a solicitation to buy or an offer to sell any securities or futures in any jurisdiction where the offer or solicitation would be unlawful under the laws of such jurisdiction. Nothing contained in this communication constitutes tax, legal or investment advice. Investors must consult their tax adviser or legal counsel for advice and information concerning their particular situation. Cboe Global Markets, Inc. and its affiliates make no warranty, expressed or implied, including, without limitation, any warranties as of merchantability, fitness for a particular purpose, accuracy, completeness or timeliness, the results to be obtained by recipients of the products and services described herein, or as to the ability of the indices referenced in this press release to track the performance of their respective securities, generally, or the performance of the indices referenced in this press release or any subset of their respective securities, and shall not in any way be liable for any inaccuracies, errors. Cboe Global Markets, Inc. and its affiliates have not calculated, composed or determined the constituents or weightings of the securities that comprise the third-party indices referenced in this press release and shall not in any way be liable for any inaccuracies or errors in any of the indices referenced in this press release. There are important risks associated with transacting in any of the Cboe Company products discussed here. Before engaging in any transactions in those products, it is important for market participants to carefully review the disclosures and disclaimers contained at: Options involve risk and are not suitable for all market participants. Prior to buying or selling an option, a person should review the Characteristics and Risks of Standardized Options (ODD), which is required to be provided to all such persons. Copies of the ODD are available from your broker or from The Options Clearing Corporation, 125 S. Franklin Street, Suite 1200, Chicago, IL 60606. View original content to download multimedia: SOURCE Cboe Global Markets, Inc.
The Drive
6 minutes ago
- The Drive
GM Says Nurburgring Lap Times Still Matter. Here's Why It's Right
The latest car news, reviews, and features. Shocking nobody, GM has gone on record this week saying that Nürburgring lap times still matter. When you're spending millions of dollars on something, that says plenty on its own. But if you're paying somebody as talented as Bob Sorakanich to do your talking for you, you might as well let the man cook. I won't rehash his points here; they're precisely what you'd expect from a company that is locked in an expensive development battle with a cross-town rival. And say what you will about the current state of the automotive industry, but this game of lap time leapfrog is a breath of fresh air in an industry that is facing what amounts to a crisis of passion. But there's hope on that front, even if it comes in unusual forms. So long as there are engineers who want to be the best at what they do, that hunger will always manifest itself. We don't need the 'Ring to keep the automakers passionate. We need it to keep them honest . Ford Say what you will about what 'Ring-focused development has done to the modern luxury car. No, really. You're right. For the vast majority of cars developed at least in part at what amounts to Germany's least efficient toll road, the lap time itself is entirely irrelevant. If anything, many automakers are trying to stretch their time on track in an effort to learn as much as possible about the real-world performance of the cars they're testing. Save for a precious few, the countless prototypes we see testing somewhere in or around the facility will never grace its record board. And many things we now take for granted are a product of the 'Ring, its green hills rising like a high-performance tide, lifting the collective expectations of buyers who have been trained that newer must be bigger, faster, and more expensive. It's a mixed bag, I'll readily admit. I hate putting new summer tires on 20- and 21-inch wheels just as much as you do. But in an information climate where corporations are being empowered to set narratives as they see fit, the 'Ring remains a reliable anchor point. Words are cheaper than they've ever been; paying Bob to say Chevy believes in the 'Ring costs a lot less than actually taking a car there to prove it, that's for sure. So, as long as automakers remain willing to put their money where their mouth is, I say hell yes, 'Ring times still matter. And you should too. Got a tip on an automaker putting its money where their mouth is? Hit us up at tips@ .
Yahoo
34 minutes ago
- Yahoo
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, 2025
LAUSANNE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, August 12, 2025, at 8:30 a.m. EDT to report financial results for the second quarter of 2025 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the event, though you may pre-register at any time. A live webcast of the call will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at The archived webcast will be available for 30 days following the call. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA and a PSMA-targeting ADC. ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker. Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at and follow us on LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future compendia and regulatory strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS 5 and 7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; and the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. CONTACTS:Investors and MediaNicole RileyADC 862-926-9040 View original content to download multimedia: SOURCE ADC Therapeutics SA Sign in to access your portfolio
